Compare abrdn Physical Palladium Shares ETF (PALL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Physical Palladium Shares ETF vs TransMedics Group Inc — how do they compare? abrdn Physical Palladium Shares ETF trades at $20.77 (market cap $586.03M), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 4.7× abrdn Physical Palladium Shares ETF's market cap, and TransMedics Group Inc is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold abrdn Physical Palladium Shares ETF for 33 Days and TransMedics Group Inc for 24 Days on average.
| PALL | TMDX | |
|---|---|---|
Market Cap | $586.03M | $2.74B |
Volume | 1,257,028 | 949,331 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $37.18 | $150.42 |
52-Week Low | $20.30 | $61.99 |
Typical Hold Time | 33 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PALL trades at $20.49, up 0.94% today, but technical indicators signal a bearish trend with moving averages unanimously negative. Recent news highlights palladium's underperformance versus other precious metals, with some analysts viewing current price weakness as a buying opportunity due to supply risks and industrial demand potential. Financial ratios are unavailable, limiting fundamental assessment.
The outlook remains cautious; while oversold RSI levels suggest potential for a rebound, bearish momentum dominates. Key risks include commodity price volatility and reliance on industrial demand. Investors should weigh technical weakness against contrarian bullish arguments from recent analyst coverage.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
